Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva Licenses Cephalon PARP Inhibitor To Checkpoint Therapeutics

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries Ltd. has licensed an oral PARP inhibitor originally developed by Cephalon to Fortress Biotech company, Checkpoint Therapeutics, Inc. one of several subsidiary companies of Fortress Biotech, Inc. Checkpoint will obtain exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, oral PARP (poly ADP-ribose polymerase) inhibitor, CEP-9722, which is in early clinical development for solid tumors.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register